Argenx’s Vyvgart tops Trinity’s latest launch success analysis, beating out several Big Pharma debuts
Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, according to the latest edition of Trinity Life Sciences’ annual Drug Index. The report looked at several factors to rank the industry's top launches from 2021.
Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, according to the latest edition of Trinity Life Sciences’ annual Drug Index. The report looked at several factors to rank the industry's top launches from 2021.
